Advanced Proteome Therapeutics Corporation
APCH.V
TSX
| 04/30/2023 | 01/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -52.57% | 42.36% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.36% | 9.70% | |||
| Operating Income | 50.36% | -9.70% | |||
| Income Before Tax | -351.35% | -28.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -351.35% | -28.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -56.02% | 12.30% | |||
| Net Income | -431.62% | -32.57% | |||
| EBIT | 50.36% | -9.70% | |||
| EBITDA | 50.16% | -9.71% | |||
| EPS Basic | -426.09% | -30.19% | |||
| Normalized Basic EPS | 52.94% | -21.43% | |||
| EPS Diluted | -426.09% | -30.19% | |||
| Normalized Diluted EPS | 52.94% | -21.43% | |||
| Average Basic Shares Outstanding | 1.00% | 1.59% | |||
| Average Diluted Shares Outstanding | 1.00% | 1.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
